在心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭患者中,心力衰竭
Christian Jörg Rustenbach1, Stefan Reichert1, Medhat Radwan1
1Department of Thoracic and Cardiovascular Surgery, German Cardiac Competence Center, Eberhard-Karls-University of Tuebingen, 72076 Tübingen, Germany.
Biomedicines
|November 25, 2023
概括
与式冠状动脉旁路移植 (ONCAB) 相比,非式冠状动脉旁路移植 (OPCAB) 为排气分数减少的患者提供了改善的术后结果. 这两种方法都显示了类似的30天死亡率,但OPCAB减少了通风时间和ICU停留时间.
科学领域:
- 心血管外科心血管外科
- 心脏外科手术的结果
- 最少侵入性的心脏手术
背景情况:
- 减少喷射分数 (<40%) 在冠状动脉旁路移植 (CABG) 中带来了挑战.
- 将内 (ONCAB) 和外 (OPCAB) 技术进行比较对于优化患者的治疗结果至关重要.
研究的目的:
- 为了比较ONCAB和OPCAB之间的术后结果和30天死亡率,在减少喷射分数的患者中.
- 评估OPCAB的安全性和有效性,作为这种高危人群中ONCAB的替代品.
主要方法:
- 从2017年1月到2021年12月,在德国四所大学医院对551名患者进行隔离CABG的回顾性分析.
- 在ONCAB和OPCAB组之间对人口统计,手术内和术后数据进行比较.
- 包括减少喷射分数 (<40%) 的患者.
主要成果:
- 没有观察到人口统计学差异;然而,OPCAB患者的手术前功能衰竭和急诊率较高.
- 在ONCAB组实现更高的完整再血管化率,而OPCAB需要更少的输血.
- 在ONCAB和OPCAB组之间30天/住院死亡率没有显著差异.
- OPCAB组的机械呼吸时间显著缩短,ICU停留时间减少,ECLS,AKI,痴呆症和败血症的发病率降低.
结论:
- OPCAB手术是对ONCAB的安全有效替代方案,用于减少喷射分数的患者.
- OPCAB提供了改善的术后恢复,包括更短的通风和ICU持续时间,死亡率可比.
- 这些发现支持OPCAB作为患有冠状动脉心脏病和减少射出分数的患者的有益方法.
相关概念视频
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.